Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin Announces Q2, 2011 Results Conference Call
Conference Call Set for 8:00 am EDT, August 10
View HTML
Toggle Summary Phase 3 ANCHOR and MARINE Trial Data to be Presented in November at the American Heart Association's Scientific Sessions
Two Abstracts With Oral Presentations Scheduled for ANCHOR and MARINE Results
View HTML
Toggle Summary Amarin Successfully Completes All Remaining Clinical Studies for AMR101 NDA
NDA On-Track to be Submitted in Current Quarter
View HTML
Toggle Summary Amarin Completes All Non-Clinical Work for AMR101 NDA Submission
Company Progresses Toward Regulatory Submission This Quarter
View HTML
Toggle Summary Amarin to Present at the Jefferies 2011 Global Healthcare Conference
MYSTIC, Conn. and DUBLIN, Ireland , June 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski , Amarin's Executive Chairman and Chief Executive Officer, will
View HTML
Toggle Summary Amarin Announces Global Supply Network for AMR101
Company Adds Multiple Suppliers to Increase Capacity and Flexibility in Preparation for Commercial Launch of AMR101
View HTML
Toggle Summary Additional Detail of Successful MARINE Phase III Trial to be Presented at the National Lipid Association 2011 Annual Scientific Sessions
Data Presented for Secondary and Exploratory Endpoint of Pivotal Study of AMR101 Includes Statistically Significant Reductions Compared to Placebo for Important Lipid Biomarkers
View HTML
Toggle Summary Amarin-Sponsored Posters to be Presented Today at the National Lipid Association 2011 Annual Scientific Sessions
-EPA Therapy Demonstrates a Wide Range of Lipid Lowering Benefits Without the LDL-C Increase as Seen With Omega-3s Containing DHA- - Amarin's AMR101 Contains >96% EPA - NEW YORK , May 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with
View HTML
Toggle Summary Amarin Reports First Quarter 2011 Results
-Successful Phase 3 Clinical Program for AMR101 Positions Company for NDA Filing in Q3-- Conference Call Set for 8:00 am EDT Today, May 10 -
View HTML
Toggle Summary Amarin to Present at the Deutsche Bank 26th Annual Healthcare Conference
MYSTIC, Conn. and DUBLIN , April 26, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John Thero , Amarin 's President, will present at the Deutsche Bank 26th Annual Healthcare
View HTML

Amarin Corporation